Skip to main content
OpenTrials
Completed

NCT Number: NCT01989624

PAncreatic Adenocarcinoma in Hospital

Few data are currently available in the literature on pancreatic adenocarcinoma in France. About 8,000 new cases each year in France. The 5-year survival for all stages combined is <5%. This is the only digestive cancer in which mortality / incidence ratio is 98%.

Epidemiological characteristics at diagnosis, the impact on the survival of recent advances related to surgery, adjuvant chemotherapy and new standard forms of adjuvant chemotherapy (FOLFIRINOX) are mispriced in real life.

The development of new drugs and the development of Phase II and III require a better understanding of the state of this disease in the country.

The main objective is to describe the characteristics of the pancreatic adenocarcinoma at diagnosis in France and make an inventory of diagnostic practices and support.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pancreatic Adenocarcinoma Disease Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CH de Jolimont, Jolimont, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Living in France
  • Pancreatic adenocarcinoma histologically or cytologically proven
  • primary diagnosis
  • Agreed to participate

Exclusion criteria

  • Suspected pancreatic adenocarcinoma histologically or cytologically unproven
  • Refused to participate

Treatment and study plan

Primary outcomes

  1. Survival

    Time frame: patient death (following during 5 year)

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Departemental Vendee

Other

Registry information

Acronym: APACH

Important dates

Study start
2013
Primary completion
2015
Study completion
2020
First posted
Nov 21, 2013
Registry last updated
Mar 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.